Kairos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020
Cash & Equivalents	4.49	1.27	0.09	0.44	0.07	Upgrade
Cash & Short-Term Investments	4.49	1.27	0.09	0.44	0.07	Upgrade
Cash Growth	253.07%	1267.74%	-78.72%	498.63%	410.20%	Upgrade
Prepaid Expenses	0.05	0.04	0.01	-	-	Upgrade
Other Current Assets	0.85	2.86	-	-	-	Upgrade
Total Current Assets	5.39	4.17	0.1	0.44	0.07	Upgrade
Other Intangible Assets	0.06	0.22	0.38	0.54	0.7	Upgrade
Long-Term Deferred Charges	1.09	1.38	0.48	0.06	-	Upgrade
Total Assets	6.54	5.77	0.97	1.04	0.78	Upgrade
Accounts Payable	0.2	0.99	2.4	1.63	1.55	Upgrade
Short-Term Debt	-	-	0	0	0.39	Upgrade
Total Current Liabilities	0.2	0.99	2.41	1.63	1.94	Upgrade
Long-Term Debt	-	-	0.64	0.58	-	Upgrade
Total Liabilities	0.2	0.99	3.04	2.22	1.94	Upgrade
Common Stock	0.02	0.01	0.01	0.01	0.1	Upgrade
Additional Paid-In Capital	20.58	13.58	4.12	3.21	2.08	Upgrade
Retained Earnings	-14.26	-8.82	-6.21	-4.4	-3.35	Upgrade
Shareholders' Equity	6.34	4.78	-2.08	-1.18	-1.17	Upgrade
Total Liabilities & Equity	6.54	5.77	0.97	1.04	0.78	Upgrade
Total Debt	-	-	0.64	0.59	0.39	Upgrade
Net Cash (Debt)	4.49	1.27	-0.55	-0.15	-0.32	Upgrade
Net Cash Growth	253.07%	-	-	-	-	Upgrade
Net Cash Per Share	0.24	0.11	-0.05	-0.01	-0.04	Upgrade
Filing Date Shares Outstanding	21.41	16.69	10.56	10.33	12.08	Upgrade
Total Common Shares Outstanding	20.82	13.74	10.56	10.33	12.08	Upgrade
Working Capital	5.19	3.18	-2.3	-1.2	-1.87	Upgrade
Book Value Per Share	0.30	0.35	-0.20	-0.11	-0.10	Upgrade
Tangible Book Value	6.28	4.55	-2.46	-1.72	-1.87	Upgrade
Tangible Book Value Per Share	0.30	0.33	-0.23	-0.17	-0.15	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.